The American College of Rheumatology meeting, held in Atlanta, Georgia, from November 7 to November 11, 2010, presented some modest new advances in the understanding of osteoporosis.
Osteoarthritis is characterized by the gradual wear and tear of the articular cartilage, the thorn that covers the ends of the long bones. Osteoarthritis primarily affected weight-bearing areas such as the neck, lower back, hips, and knees.
Osteoarthritis is the most common form of arthritis and affects more than 20 million Americans and is expected to increase in frequency as children continue to age.
The goal of osteoporosis treatment is pain relief and improved function. However, the end goal has always been to restore the meniscus.
Some of the highlights from this year’s meetings were:
1. Proving that genetic markers called ‘SNPs’ may provide clues as to why some people develop osteoporosis more easily than others. Therefore, in addition to cartilage injury, which is a known risk factor for osteoarthritis, there also appears to be a genetic tendency to develop the disease. Perhaps, in the future, patients at risk of developing osteoporosis may be identified and treated more aggressively.
2. Cymbalta (duloxetine), a drug already approved by the U.S. Food and Drug Administration for the treatment of major depressive disorder, fibromyalgia, and diabetic peripheral neuropathy, and has been approved by the U.S https://www.opalphysio.ca/7-strategies-for-hip-and-knee-osteoarthritis/. Food and Drug Administration for the treatment of chronic musculoskeletal pain, including pain Resulting from osteoporosis and chronic lower back pain. The efficacy of Cymbalta for chronic low back pain and osteoarthritis was evaluated in four randomized, double-blind, placebo-controlled clinical trials. Patients who took Cymbalta in these trials experienced greater pain reduction compared to the placebo.
3. Data have been presented on Naproxcinod, a unique non-steroidal anti-inflammatory drug. Naproxenode is the first nitric oxide-donor cyclooxygenase (CINOD) inhibitor in development for the treatment of osteoporosis. It was found to be comparable to naproxen in its ability to relieve hip osteoarthritis pain, while causing less negative effects on blood pressure.
4. The famous “new kid on the block,” Vitamin D, took a hit to his reputation. Vitamin D supplementation was not successful in helping patients with osteoarthritis of the knee cope with pain in one study from Tufts University.
5. The use of ultrasound-guided knee injections for osteoarthritis resulted in a 42 percent reduction in pain, a twofold response rate to treatment, and a 15 percent reduction in cost for patients, compared to conventional “feel”-guided injections.
6. Pennsaid, a relatively new topical agent that combines the anti-inflammatory effects of diclofenac with the penetrating power of DMSO, has provided some encouraging data on pain relief for osteoarthritis of the knee.
7. Another study showed that Lidoderm patches provide other possible options for relieving knee osteoarthritis pain and were better than placebo.
8. Researchers from Rush Medical School in Chicago recently studied the gait of 16 adults diagnosed with osteoarthritis of the knees by X-ray and reported symptoms. Researchers have found that special shoes can relieve knee pain and slow the progression of knee pain and arthritis.
9. A study from the Netherlands showed that knee distraction (using pins to open the knee joint) actually led to cartilage growth and improved symptoms as well as avoiding the need for a knee replacement.